@article{8ceae2536ab447fb9c5d8002e53153e2,
title = "Improving MS patients{\textquoteright} understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial",
keywords = "disease-modifying drugs, medical decision making, Multiple sclerosis, randomised crossover trial, treatment understanding",
author = "Reen, \{Gurpreet K.\} and Eli Silber and Langdon, \{Dawn W.\}",
note = "Funding Information: This study was supported by an investigator initiated research grant from Biogen and matched funding from Royal Holloway, University of London . The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript, beyond courtesy review. Funding Information: GR has no disclosures. ES had acted as an advisor or received financial support for research and for educational purposes, and hospitality, from Merck-Serono, Biogen, TEVA, Bayer-Schering and Novartis; and through his NHS trust has also received financial support for projects/service developments from some of these companies. He has been an investigator in commercial trials sponsored by Biogen Idec, Novartis, TEVA, Receptos, Roche, GW Pharma and GSK. DL's disclosures are: Consultancy from Celgene, Novartis, Bayer, TEVA; Speaker bureau for Almirall, TEVA, Biogen, Novartis, Bayer; Research grants from Novartis, Biogen, Bayer. Funding Information: This study was supported by an investigator initiated research grant from Biogen and matched funding from Royal Holloway, University of London. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript, beyond courtesy review. Publisher Copyright: {\textcopyright} 2021 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = apr,
doi = "10.1016/j.msard.2021.102737",
language = "English",
volume = "49",
journal = "Multiple sclerosis and related disorders",
issn = "2211-0348",
publisher = "Elsevier B.V.",
}